ELOX Eloxx Pharmaceuticals, Inc.

NASDAQ
$12.92

Eloxx Pharmaceuticals, Inc. (ELOX) is expected to report earnings on November 16, 2026, after the market close. The stock has had a Post-Earnings Announcement Drift (PEAD) of -34.8% since its last earnings release on August 11, 2026.

Eloxx Pharmaceuticals Reported Earnings
Wednesday, August 12, 2026 · 6:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 4:15 PM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.34

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.